v2.3.0.11
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $)
In Millions, except Per Share data
 3 Months Ended 6 Months Ended
Jul. 03, 2011
Jul. 04, 2010
Jul. 03, 2011
Jul. 04, 2010
Revenues $ 16,984 $ 17,132 $ 33,486 $ 33,708
Costs and expenses:        
Cost of sales 3,805 [1] 3,684 [1] 7,498 [1] 7,886 [1]
Selling, informational and administrative expenses 4,973 [1] 4,774 [1] 9,476 [1] 9,177 [1]
Research and development expenses 2,237 [1] 2,181 [1] 4,328 [1] 4,402 [1]
Amortization of intangible assets 1,395 1,407 2,771 2,816
Acquisition-related in-process research and development charges       74
Restructuring charges and certain acquisition-related costs 479 [2] 885 [2] 1,373 [2] 1,591 [2]
Other deductions--net 413 275 1,240 687
Income from continuing operations before provision for taxes on income 3,682 [3] 3,926 [3] 6,800 [3] 7,075 [3]
Provision for taxes on income 1,094 1,472 1,988 2,607
Income from continuing operations 2,588 2,454 4,812 4,468
Discontinued operations:        
Income from operations--net of tax 30 31 40 50
Gain on sale of discontinued operations--net of tax       2
Discontinued operations--net of tax 30 31 40 52
Net income before allocation to noncontrolling interests 2,618 2,485 4,852 4,520
Less: Net income attributable to noncontrolling interests 8 10 20 19
Net income attributable to Pfizer Inc. $ 2,610 $ 2,475 $ 4,832 $ 4,501
Earnings per share--basic:        
Income from continuing operations attributable to Pfizer Inc. common shareholders $ 0.33 $ 0.30 $ 0.60 $ 0.55
Discontinued operations--net of tax (in dollars per share)     $ 0.01 $ 0.01
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.33 [4] $ 0.31 [4] $ 0.61 [4] $ 0.56 [4]
Earnings per share--diluted:        
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.33 $ 0.30 $ 0.60 $ 0.55
Discontinued operations--net of tax (in dollars per share)     $ 0.01 $ 0.01
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) $ 0.33 [4] $ 0.31 [4] $ 0.61 [4] $ 0.56 [4]
Weighted-average shares used to calculate earnings per common share:        
Basic (in shares) 7,875 8,046 7,929 8,053
Diluted (in shares) 7,935 8,072 7,980 8,085
Cash dividends paid per common share (in dollars per share) $ 0.20 $ 0.18 $ 0.40 $ 0.36
[1] Exclusive of amortization of intangible assets, except as disclosed in Note 11B. Goodwill and Other Intangible Assets: Other Intangible Assets.
[2] From the beginning of our cost-reduction and transformation initiatives in 2005 through July 3, 2011, Employee termination costs represent the expected reduction of the workforce by approximately 55,400 employees, mainly in manufacturing and sales and research, of which approximately 39,100 employees have been terminated as of July 3, 2011. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities. These restructuring charges in 2011 are associated with the following: ● For the three months ended July 3, 2011, Primary Care operating segment ($87 million), Specialty Care and Oncology operating segment ($7 million), Established Products and Emerging Markets operating segment ($12 million), Animal Health and Consumer Healthcare operating segment ($4 million), research and development operations ($51 million), manufacturing operations ($81 million) and Corporate ($23 million). ● For the six months ended July 3, 2011, Primary Care operating segment ($133 million), Specialty Care and Oncology operating segment ($42 million), Established Products and Emerging Markets operating segment ($15 million), Animal Health and Consumer Healthcare operating segment ($14 million), Nutrition operating segment ($2 million), research and development operations ($473 million), manufacturing operations ($156 million) and Corporate ($135 million).
[3] Income from continuing operations before provision for taxes on income.
[4] EPS amounts may not add due to rounding.